Our leaders

Percy brings more than 20 years of global leadership in pharmaceutical companies and industry experience. Prior to joining Blueprint Medicines, he served as Chief Scientific Officer at FibroGen, Inc. He previously served as Global Head of Discovery Sciences at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he led more than 700 employees comprising several key research and discovery functions, and drove the synthetic discovery strategy in collaboration with partners across various therapeutic areas. From August 2001 to May 2019, Percy held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug platforms and stages of discovery at Bristol-Myers Squibb (BMS), including serving as Senior Vice President and Head of Discovery. Prior to his experience at BMS, he was Senior Research Scientist in Chemical and Physical Sciences at DuPont Pharmaceuticals, until it was acquired by BMS in 2001. Percy is an inventor or co-inventor on more than 28 U.S. patents, and has authored or co-authored numerous peer-reviewed publications. Percy currently serves as a member of the board of directors for Cellarity and HiFiBiO Therapeutics. He received an A.B. in Chemistry from Dartmouth College and a Ph.D. in Organic Chemistry from Harvard University. In addition, he received an MBA from Massachusetts Institute of Technology.

Helen brings more than 15 years of pharmaceutical and biotechnology industry experience with a strong track record in business development, corporate growth strategy and operations. She joined Blueprint Medicines in April 2018, previously serving as Senior Vice President, Corporate Development accountable for business development, alliance management and new product planning. In her present role, she is responsible for driving the company’s corporate strategy, leading Business Development and Portfolio Strategy & Program Management. Prior to joining Blueprint Medicines, Helen served as Vice President, Head of Corporate Development at TCR2 Therapeutics. She led portfolio strategy, business development and investor & public relations which culminated in closing of $125M Series B crossover financing. Prior to TCR2 Therapeutics, Helen was the Director, Business Development & Operations at Agios Pharmaceuticals where she played a broad role in company building having led the business development licensing function, supported company’s IPO and building of its Rare Genetic Disorders and Immuno-Oncology franchises. Previously, Helen was a management consultant at L.E.K. Consulting, leading projects from both Boston and Shanghai offices. She currently serves as a Board Observer at IDRx, Inc. Helen holds a Ph.D. in Cell Biology from Yale University and B.S. in Biochemistry from University of California, Los Angeles.

Philina brings more than 15 years of biopharmaceutical industry leadership experience, with a strong track record of product commercialization and successfully building high growth organizations while fostering a strong company culture. Since April 2022, Philina has served as Chief Commercial Officer of Blueprint Medicines. She joined Blueprint Medicines in August 2014 as Senior Director, New Product Strategy and Development and subsequently held multiple commercial roles with responsibility for strategy, operations, patient services, marketing and the precision medicine field team. During her tenure, she has been instrumental in building the company’s portfolio from research-stage onwards, laying the groundwork for the commercial strategy that is driving the successful launches of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib). From January 2021 to April 2022, she served as Senior Vice President, Head of Portfolio Strategy and Program Management, where she was responsible for providing strategic and operational leadership across the company’s portfolio. Previously, Philina held product strategy and marketing roles of increasing responsibility at Algeta, Sanofi and Genzyme. She serves on the board of Fusion Pharmaceuticals, as a member of both the Nomination and Governance committee and Research and Development committee. Philina earned a B.S. in Biochemistry from the University of Alberta, and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.

Georg P. Meyer, M.D., holds more than two decades of biotechnology and pharmaceutical experience as a strategic innovator and visionary leader, with a track record of driving high-impact sales and marketing strategies, overseeing pricing and market access initiatives across international markets, and leading cross-functional teams, including medical affairs. Since 2021, Georg has served as Senior Vice President, Head of International at Blueprint Medicines, where he oversees strategic and tactical operations for international regions, including financial planning and commercial leadership. In this role, he leads cross-functional initiatives and drives international business operations towards financial sustainability, overseeing employees in European countries and select partners in expansion markets. From 2019 to 2021, Georg served as Vice President and General Manager, Germany, Austria and Switzerland (DACH) at Blueprint Medicines. In this role, he co-created innovative late-stage pipeline solutions and managed commercial geographic expansions, including access strategies and supply chain infrastructure. Prior to that, Georg served as General Manager, Germany at Vertex Pharmaceuticals, and he held various roles of increasing responsibility at Amgen and Sanofi-Synthelabo. Georg earned his M.D. from partnered institutions University of Freiburg, Germany and University of Innsbruck, Austria.